Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia, cold agglutinin disease, sickle cell disease and other rare blood disorders. Founded on a legacy of scientific innovation, world-class science and a deep commitment to the rare blood disorders community, Bioverativ is focused on creating progress for patients where they need it most. Our hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit bioverativ.com or follow @bioverativ on Twitter.